New Rufomycins from Streptomyces atratus MJM3502 Expand Anti- Mycobacterium tuberculosis Structure-Activity Relationships
journal contribution
posted on 2023-03-15, 22:17 authored by Bin Zhou, Gauri Shetye, Nina M. Wolf, Shaonong ChenShaonong Chen, Mallique Qader, G. Joseph Ray, David C. Lankin, Sang Hyun ChoSang Hyun Cho, Jinhua Cheng, Joo-Won Suh, Scott FranzblauScott Franzblau, James B. McAlpine, Guido PauliGuido PauliFour new rufomycins, compounds 1-4, named rufomycins 56, 57, 58, and 61, respectively, exhibiting new skeletal features, were obtained from Streptomyces atratus strain MJM3502 and were fully characterized. Compounds 1 and 2 possess a 4-imidazolidinone ring not previously encountered in this family of cyclopeptides, thereby resulting in a [5,17] bicyclic framework. The in vitro anti-Mycobacterium tuberculosis potency of compounds 3 and 4 is remarkable, with minimum inhibitory concentration values of 8.5 and 130 nM, respectively.
Funding
“Targeting Protein Degradation ClpC1 ATPase” | Funder: National Institutes of Health | Grant ID: U19AI142735
History
Citation
Zhou, B., Shetye, G., Wolf, N. M., Chen, S. N., Qader, M., Ray, G. J., Lankin, D. C., Cho, S., Cheng, J., Suh, J. W., Franzblau, S. G., McAlpine, J. B.Pauli, G. F. (2022). New Rufomycins from Streptomyces atratus MJM3502 Expand Anti- Mycobacterium tuberculosis Structure-Activity Relationships. Organic Letters, 24(40), 7265-7270. https://doi.org/10.1021/acs.orglett.2c02493Publisher
American Chemical Society (ACS)Language
- en
issn
1523-7060Usage metrics
Categories
No categories selectedKeywords
3404 Medicinal and Biomolecular Chemistry34 Chemical SciencesInfectious DiseasesTuberculosisRare DiseasesHIV/AIDS3 Good Health and Well BeingAntitubercular AgentsHumansMicrobial Sensitivity TestsMycobacterium tuberculosisOligopeptidesPeptides, CyclicStreptomycesStructure-Activity RelationshipOrganic Chemistry34 Chemical sciencesChemical Sciences
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC